Barriers and facilitators to enrollment in cancer clinical trials

Abstract

BACKGROUNDThe literature continues to report low rates of accrual to cancer clinical trials. Previous studies have examined principally physician‐related or patient‐related barriers. Clinical research associates (CRAs) have a unique perspective on enrollment that has been explored very little. This study sought the views of CRAs on barriers and facilitators to accrual.METHODSFocus groups were held at six of eight tertiary cancer centers in Ontario, Canada. Audiotapes of sessions were transcribed and subjected to content analysis by two of the authors. Emergent themes were identified. These themes are illustrated by representative quotes taken from the transcripts.RESULTSFactors that acted as barriers or facilitators were classified into physician‐related, patient‐related, or system‐related factors. CRAs identified physician attitudes regarding patient participation as the principal physician‐related barrier. Barriers, facilitators, and modifying factors that were related to patient involvement were discussed by CRAs. Patients seemed more knowledgeable about trials than in the past and were willing to participate. System factors were considered to have the greatest impact on the ability to accrue. CRAs identified increasing trial and pharmaceutical demands coupled with tight trial time lines. Time was seen as a diminishing resource. Greater demands not only affect specific clinical trial accrual but also affect general support for trials in the cancer center and hospital.CONCLUSIONSThe impact of greater demands in a climate of decreasing health care resources is perceived by CRAs as having a negative affect on accrual. Consequently, the important process of translating potentially beneficial basic research findings into clinical practice is slowed. Cancer 2002;95:1577–83. © 2002 American Cancer Society.DOI 10.1002/cncr.10862

Attitude towards clinical trials: Results of a survey of persons interested in research

“…In the literature there is a differentiation between doctor, patient and system factors [14]. A review article differentiated between logistic problems (e.g.…”

Testing Three Different Cancer Genetics Registry Recruitment Methods with Hispanic Cancer Patients and Their Family Members Previously Registered in Local Cancer Registries in Texas

“…This study was conducted to better understand the barriers to Hispanic participation in cancer registries and, to some degree, clinical trial participation. Limited data found in existing literature suggest that key barriers to minority recruitment into clinical trials include lack of education and mistrust of research [3,4,5,6,7,8,9,10,11], researchers, and the medical system [4,7,8,9,10,11,12,13,14,15,16]. Among others are lack of health insurance [12,17,18,19], low income and indirect costs to participation [15,16,17,18,19,20], and age [21,22,23,24].…”

“…A comprehensive literature review by Ford et al [25] has shown that perceived harm of clinical trial participation and fear are among the most frequently reported barriers that minimize clinical trial participation. Some promoters of clinical trial participation among minorities include provider incentives [5, 8, 9], altruism [3, 9, 13, 14, 26], and culturally relevant education about clinical trials [25]. …”

Bioethics in biotechnology: from pain to gain

“…Indeed, it was found that enrollment was low in clinical trials conducted by companies with ''bad press'' due to a corporation's reputation. When clinical research associates thought it worthwhile to survey their colleagues to identify the issues that encourage or discourage individuals to participate in corporate sponsored clinical trials, an important impediment was identified in the focus groups: negative media coverage can drop a study's accrual rate to zero [Grunfeld et al, 2002].…”